<DOC>
	<DOCNO>NCT00000852</DOCNO>
	<brief_summary>To examine , HIV-infected patient , safety allogeneic lymphocyte transfer ( i.e. , infusion white blood cell take HIV-negative parent , sibling , adult offspring compatible blood type ) . To measure distribution survival allogeneic lymphocytes circulation HIV-infected patient , determine whether infusion result enhance immunity . To determine whether enhanced immunity passively transfer actively induce . There evidence periodic infusion allogeneic lymphocyte obtain peripheral blood HLA-matched HIV-1 seronegative sibling patient AIDS , instance , restore number circulate CD4+ lymphocyte . However , control study need well quantitate immunologic reconstitution see type therapy .</brief_summary>
	<brief_title>A Pilot Study Allogeneic Lymphocyte Transfer HIV Infection</brief_title>
	<detailed_description>There evidence periodic infusion allogeneic lymphocyte obtain peripheral blood HLA-matched HIV-1 seronegative sibling patient AIDS , instance , restore number circulate CD4+ lymphocyte . However , control study need well quantitate immunologic reconstitution see type therapy . Lymphocytes obtain leukapheresis healthy , HIV-negative parent , sibling , adult offspring HIV-infected patient infuse day 0 week 4 8 . A small portion lymphocyte obtain day 0 radiolabeled prior infusion , two total body scan perform . Patients also undergo two tonsillar biopsy . Patients follow weekly 16 week , telephone periodically 3 year ( 1 year , 2 year , 2.5 year , 3 year ) .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Required : Stable antiretroviral therapy . Allowed : Maintenance therapy control opportunistic infection . Patients must : HIV infection . CD4 count 50200 cells/mm3 . No ongoing major opportunistic infection . Been stable antiretroviral therapy past 2 month . Tonsils present . Life expectancy great 6 month . An HLAsingle haplotype match , single haplotype mismatch parent , sibling , adult offspring ABO , Rh compatible serve HIVnegative lymphocyte donor . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Lymphoma malignancy require chemotherapy . Bleeding disorder would preclude tonsillar biopsy . Antibody donor/recipient lymphocyte reactive antibody assay . Donors follow symptoms condition exclude : Medical condition would endanger health donor recipient . Failure meet establish donor standard blood screening test . CMV seropositivity patient ( recipient ) CMV seronegative . Pregnancy . Concurrent Medication : Excluded : GMCSF GCSF . Any investigational drug . Immunomodulators ( interferon , steroid , topical corticosteroid , thalidomide , pentoxifylline , IL2 ) . Nonsteroidal antiinflammatory drug . Aspirin . Prior Treatment : Excluded : Blood transfusion within past 2 month . Required : Stable antiretroviral therapy least 2 month prior study entry . Active substance abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 1998</verification_date>
	<keyword>T-Lymphocytes</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Transplantation , Homologous</keyword>
	<keyword>Immunotherapy , Adoptive</keyword>
</DOC>